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Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism
in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings
than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and,
therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has
been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of
Argentina, are still scarce.
We performed a cost-effectiveness analysis of apixaban versus warfarin in non-valvular atrial fibrillation (NVAF) in
patients suitable for oral anticoagulation in Argentina. A Markov-based model including both costs and effects were
used to simulate a cohort of patients with NVAF. Local epidemiological, resource utilization and cost data were used
and all inputs were validated by a Delphi Panel of local experts. We adopted the payer’s perspective with costs
expressed in 2012 US Dollars.
The study revealed that apixaban is cost-effective compared with warfarin using a willingness to pay threshold
ranging from 1 to 3 per capita Gross Domestic Product (11558 – 34664 USD) with an incremental cost-effectiveness
ratio of 786.08 USD per QALY gained. The benefit is primarily a result of the reduction in stroke and bleeding events.
The study demonstrates that apixaban is a cost-effective alternative to warfarin in Argentina.
Keywords: Apixaban; Warfarin; Novel oral anticoagulants; Cost-effectivenessBackground
Atrial Fibrillation (AF) is one of the most frequent ar-
rhythmias in adult population. It’s estimated prevalence
is 1 – 2 % in the general population and increases to
10 % in subjects > 65 years old [1, 2]. It is associated with
a 5-fold increase in the risk of stroke and systemic em-
bolic events (i.e. pulmonary embolism and myocardial
infarction) [3]. The chance of having a stroke depends
on several risk factors which are considered in scores
like the CHADS2 (Cardiac heart failure, Hypertension,
Age, Diabetes, and Stroke) [4] or, more recently, the
CHA[2]DS[2]-VASC (cardiac failure or ejection fraction
<40 %, high blood pressure, age 64 to 74 or ≥75 years,* Correspondence: marianoagiorgi@hotmail.com
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Full list of author information is available at the end of the article
© 2015 Giorgi et al. This is an Open Access arti
(http://creativecommons.org/licenses/by/4.0), w
provided the original work is properly crediteddiabetes, previous stroke or transient ischemic attack or
thromboembolic events, vascular disease, and female
sex) [5–7]. These scores constitute the basis for the deci-
sion to use medication in order to reduce embolic risk.
Until recently therapeutic options to reduce the risk of
stroke in AF included oral vitamin K antagonists
(VKAs), warfarin and acenocoumarol, and, in patients
who were unsuitable for these drugs, aspirin, alone or in
association with clopidogrel. Despite the proven efficacy
of VKAs, they have several limitations. The limitations
include failure to maintain the treatment range (an
International Normalized Ratio between 2.00 to 3.00),
which results in needing to perform regular coagulation
tests and many drug-drug interactions which are cause
of the underutilization of VKAs [8, 9]. A measure of the
quality of anticoagulation is the time in treatment range
(TTR) that indicates the time spent between an INRcle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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velop alternative treatment options. New Oral Anticoag-
ulants (NOACs), which have unique pharmacodynamic
and pharmacokinetic features that result in more stable
and predictable anticoagulant effect [10] are recent treat-
ment options to reduce the risk of stroke in AF. Cur-
rently, there are four NOACs (dabigatran, apixaban,
rivaroxaban, and edoxaban) that completed phase III re-
search programs and proved their safety and efficacy
[11]. All of these assets except edoxaban have received
medical approval for the use in AF in both the United
States and Europe. Apixaban, an oral factor Xa inhibitor
is the most recent compound to receive medical ap-
proval for the prevention of thrombotic events in AF in
US and Europe. In one clinical trial for apixaban, ARIS-
TOTLE, Apixaban demonstrated that it is superior to
dose-adjusted warfarin in patients suitable for oral anti-
coagulants [12]. ARISTOTLE revealed a 21 % relative
risk reduction in the primary efficacy endpoint (stroke
or systemic embolism) and a 31 % relative risk reduction
in the safety endpoint (major bleeding). Apixaban was
also compared with aspirin in patients who are unsuit-
able for oral anticoagulation in the AVERROES trial
[13]. In this study, apixaban demonstrated a 55 % rela-
tive risk reduction in the primary efficacy endpoint
(stroke or systemic embolism).
Beyond their efficacy and safety profile, the decision
for adopting apixaban by health care decision-makers
has been supported by several health economic evalua-
tions. Apixaban received a positive assessment by Na-
tional Institute of Health Care and Excellence (NICE) in
2013 [14] and several cost-effectiveness analysis have
been published revealing that apixaban, compared to ei-
ther warfarin or aspirin, is a cost-effective alternative
given a variety of health care settings [15, 16]. Given that
the estimates of about 290,000 patients with AF are suit-
able for oral anticoagulants in Argentina [17–20], it is
important to know the economic impact of new treat-
ment options. The aim of the study is to assess the cost-
effectiveness of apixaban versus VKAs in Argentina in
order to provide local data for decision-makers.
Methods
We performed an adaptation of a Markov-based cost-
effectiveness model previously submitted by the manu-
facturers of apixaban (Bristol-Myers Squibb and Pfizer)
to NICE in the UK including local epidemiological and
clinical data.
Model
The model was developed according to Good Modeling
Practices [21], a detailed description is available elsewhere
[14, 15]. The model allows a comparison of apixaban
against currently available treatment options, including:warfarin, aspirin, dabigatran, rivaroxaban, and aspirin +
clopidogrel. For the present analysis we report data for
apixaban versus warfarin for patients suitable for oral
anticoagulant therapy. The model includes 18 mutually
exclusive health states for a hypothetical cohort of patients
with non-valvular atrial fibrillation (NVAF) considering
the occurrence of stroke (both ischemic or heamorrhagic),
systemic embolism (myocardial infarction, pulmonary em-
bolism), bleeding (intracranial, major bleeding, clinically
relevant non-major bleeding) and death (Fig. 1). Transi-
tion probabilities between health states were derived from
the ARISTOTLE trial [12] and from the life expectancy
table for Argentina obtained from the World Health
Organization. [22] Patients were followed for a lifetime
horizon with 6 week cycles, with only allowing for one
event per cycle.
Population
The model considered a hypothetical cohort of 1000 pa-
tients with AF suitable for the use of oral anticoagulants.
Demographics and baseline stroke risk for the cohort
(based on the CHADS2 score) were obtained from pub-
lished reports (Table 1) [18–20, 23] and expert’s opin-
ions obtained during the Delphi Panel. Anticoagulation
quality for VKA users was considered using the average
time in therapeutic range (TTR) [24] for centers in
Argentina [Table 1] [25, 26].
Clinical event risks and management
The risk and types of clinical events included in the
model are presented in Table 2. Risks considered in the
analysis were taken from the ARISTOLE trial [12]. Is-
chemic stroke risk was adjusted per each decade of life
by a factor of 1.40 [27]. Due to inter-countries variation
in medical management and treatment patterns, a Panel
of Experts was convened using a Delphi method [28].
Two set of experts composed of 6 neurologists and 7
hematologists, representing the three health subsectors
from Argentina (public, worker´s unions health care,
and private), were consulted about clinical characteris-
tics of patients with AF, treatment patterns, prefer-
ences for treatment change in case of bleeding events
and resource utilization. All answers were revised in an
open discussion and a final set of data was obtained.
Utilities
Currently there is no local data regarding quality of life
associated with AF, stroke or any other clinical outcome
of interest. We therefore used the values from a UK cata-
logue of EQ-5D score [29] for each health state (Table 3).
Costs and resource utilization
Direct costs and resource utilization for each health state
included in the model were obtained from local data
Fig. 1 Non-valvular Atrial Fibrillation decision-tree used in the model
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able through a published report, we obtained the data
from a Health Resource Cost Database. For the eco-
nomic evaluation, we considered the perspective of the
payer. Because the Argentinean health system comprises
three health subsectors (public, worker’s unions health
care, and private), each one with its own resource
utilization pattern and prices, we reported cost as a
weighed mean. For each item we considered the price
for each health subsector multiplied by the proportion
of subjects covered by the sector: 52.5 % by the public
sector, 38.8 % by the worker’s union sector and 9 % by
the private sector [34]. For example, the reported cost of
stroke is: cost for the public sector x 0.522 + cost for the
worker’s union sector x 0.388 + price for the private sector
x 0.09.
Drug costs were obtained from local formularies and
adapted for each health subsector [30]. All prices wereupdated to the last quarter of 2012 and expressed in
2012 US Dollars (USD).
Economic analyses
We estimate the clinical effectiveness of apixaban versus
warfarin in terms of events per 1000 treated patients
using a lifetime scenario. Results were expressed as the
incremental cost-effectiveness ratio (ICER) considering a
cost effectiveness threshold between 1 to 3 per capita
GDP (Gross Domestic Product) accordingly with the
WHO-CHOICE recommendation [35]. The 2011 per
capita GDP for Argentina was estimated as 11,558 USD
[36], therefore the willingness to pay for every incremen-
tal QALY ranges from 11,558 USD to 34,674 USD. A
5 % discount rate was applied to both costs and events,
as recommended by regional regulations in 2009 [37].
Deterministic sensitivity analysis was performed and
presented as tornado graphic in order to assess the










0 10.3 % [18]
1 30.6 % [18]
2 27.0 % [23]
3 12.0 % [23]
≥4 18.1 % *
Average CHADS2 2.2
Anticoagulation Control in Centers in
Argentina (median cTTR) 51 % [24, 25]
cTTR < 52.38 %
52.38 % - 66.02 % 22 %
66.03 % - 76.51 % 22 %
cTTR≥ 76.51 % 5 %
*Assumption based on data from DiTomasso et al. [18]
Table 2 Type and risks of clinical events included in the model
(reported per 100 patient/years)
Events Apixaban Warfarin Source
Ischemic stroke risk by CHADS2 [15]
Mean 0,962 1,064
CHADS2 score 0 0,521 0,458
CHADS2 score 1 0,521 0,458
CHADS2 score 2 0,950 0,934
CHADS2 score 3 1,534 1,944
CHADS2 score 4 1,534 1,944
CHADS2 score 5 1,534 1,944
CHADS2 score 6 1,534 1,944
Systemic embolism 0.090 0.100 [12]
Hemorrhagic stroke and Intracranial
Hemorrhage
0.330 0.800 [12]
Other major bleeding 1.790 2.270 [12]
Clinically Relevant Non-Major Bleeding 2.083 2.995 [15]
Myocardial Infarction 0,530 0,610 [12]
Other hospitalizations due to
cardiovascular disease
10.460 10.460 [15]
Recurrent ischemic stroke 4.103 4.103 [43]
Recurrent hemorrhagic stroke 3.00 3.00 [43]
Table 3 Utility and utility decrements associated with health
states and treatments included in the model (measured by EQ-5D)
from reference 30
Health State Utility (SE)
Non-valvular atrial fibrillation 0.7270 (0.0095)












Utility decrements (SE/95 %
CI)
Other intracranial haemorrhage 0.1511 (0.0401)
Other major 0.1511 (0.0401)
Clinically relevant non-major bleed 0.0582 (0.0173)
Other cardiovascular hospitalization 0.1276 (0.0259)
Use of Apixaban or aspirin 0.0020 (0.00-0.04)
Use of Warfarin 0.0120 (0.00-0.08)
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effectiveness ratio.
Probabilistic sensitivity analysis was conducted changing
model’s parameters. Two thousand simulations were
ran and plotted in a cost-effectiveness plane considering
cost and QALY.
Sensitivity analyses based on the use of other AVK agent




In a VKA suitable cohort of 1000 patients with NVAF,
compared with warfarin, the use of apixaban resulted in
24 fewer strokes (including first and recurrent ischemic
and hemorrhagic) or systemic embolism, 41 fewer major
bleeding events (including first and recurrent hemorrhagic
stroke, other intracranial hemorrhage and other major
bleeds), and 26 fewer cardiovascular-related deaths
(Table 5). It is therefore estimated that 56 patients
(number needed to treat) should be treated with apixaban
over a lifetime in order to avoid one stroke (ischemic and
hemorrhagic) compared with warfarin. In addition, apixa-
ban is a better option than warfarin avoiding bleeding
events (number needed to harm = 24). The use of apixa-
ban in this target population resulted in an increase of
0.164 life years and 0.172 QALYs (Table 5).
Table 4 Drug and Event costs (in 2012 US Dollars)
Item Cost (USD) [min-max] Unit Duration of the event Source
Drugs
Apixaban 5 mg (BID) 1.49 Per day – [30]
Warfarin (5 mg/day average dose) 0.15 Per day
Monitoring Visit (applicable to warfarin only) 11.85 [9.24-14.45] Per visit – *
Routine Care 1.11 [0.86-1.35] Per visit – *
Stroke (excluding hemorrhagic stroke)
Mild [31, 32]
Acute Care 1450.33 [1131.25-1769.4] Per episode 2 weeks
Long-term Maintenance 1110.20 [865.95-1354.44] Per month Lifetime
Moderate
Acute Care 2813.25 [2194.33-3432.16] Per episode 2 weeks [31, 32]
Per month LifetimeLong-term Maintenance 1110.20 [865.95-1354.44]
Severe
Acute Care 4084.26 [3185.72-4982.79] Per episode 2 weeks [31, 32]
Per month LifetimeLong-term Maintenance 1110.20 [865.95-1354.44]
Fatal Ischemic Stroke 2813.25 [2194.33-3432.16] Per episode
Heamorrhagic Stroke
Mild
Acute Care 3740.68 [2917.73-4563.62] Per episode 2 weeks [31, 32]
Long-term Maintenance 1110.20 [865.95-1354.44] Per month Lifetime
Moderate [31, 32]
Acute Care 6731.00 [5250.18 – 8211.82] Per episode 2 weeks
Long-term Maintenance 1110.20 [865.95-1354.44] Per month Lifetime
Severe
Acute Care 13777.79 [10746.67-16808.9] Per episode 2 weeks [31]
Long-term Maintenance 1110.20 [865.95-1354.44] Per month Lifetime
Fatal Heamorrhagic Stroke 6731.00 [5250.18-8211.82] Per episode **
Systemic Embolism
Acute Care 2900.04 [2262.03-3538.04] Per episode 2 weeks [33]
Long-term Maintenance 229.11 [178.70-279.52] Per month Lifetime
Other ICH (excluding heamorrhagic stroke) 6622.09 [5165.23-8078.94] Per episode – [31, 33] *
Other Major Bleeds –
(excluding ICH)
GI Bleeds 3829.17 [2986.75-4671.58] Per episode
Non ICH and Non GI Related Major Bleeds 3829.17 [2986.75-4671.58] Per episode
– [33]
– [33]
CRNM Bleeds 2055.04 [750.7-1284.28] Per episode – [33]
Myocardial Infarction
Acute Care 2211.52 [1748.00-2797.90] Per episode – [32]
Long-term Maintenance 1110.20 [865.95-1354.44] Per month Lifetime [32] *
Other CV Hospitalization 2211.52 [1139.70-1797.70] Per episode – [32]
GI bleeds gastrointestinal bleeds; ICH intracranial hemorrhage; CRNM bleed clinically relevant non-major bleeds
*Based on a local Health Resource Cost Data Base
**we assumed that fatal stroke (both ischemic or haemorrhagic) has a cost equivalent to a moderate stroke(both ischemic or haemorrhagic) reported by
Christensen et al. [31]
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Table 5 Clinical events in the cohort of NVAF patients treated
with Apixaban and warfarin
VKA Suitable
patients
Number of events (Total
population)ischemic strock
Apixaban Warfarin
Non-fatal Mild 80 80
Non-fatal Moderate 68 73




Non-fatal Mild 4 4
Non-fatal Moderate 6 7




Non-fatal Mild 4 7
Non-fatal Moderate 6 6




Non-fatal Mild 0 0
Non-fatal Moderate 0 0












Non-fatal GI Bleeds 54 55





Clinically Relevant Non-Major Bleeds 252 287
MI
Non fatal 67 67
Fatal 8 8
Table 5 Clinical events in the cohort of NVAF patients treated
with Apixaban and warfarin (Continued)
TOTAL 75 75
Other CV Hospitalization 1.060 1.020
Other Treatment Discontinuation 579 591
Deaths
Event Related (acute) 51 65
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Table 6 presents the incremental costs of the use of apixa-
ban compared with warfarin using a lifetime horizon. In
every situation, the result falls below the willingness to
pay threshold of 11558 USD (equivalent to one per capita
GDP).
Sensitivity analysis
A one way sensitivity analysis (Fig. 2) revealed that the
risk of stroke with apixaban is the main contributor to
the cost-effectiveness. In Fig 3a and b are depicted the
results of the probabilistic sensitivity analysis. The ana-
lysis presents that apixaban is more effective and more
costly than warfarin. Considering a willingness to pay
threshold of 11,558 USD per QALY gained, apixaban is a
cost-effective alternative in 90 % of the cases. Using the
upper threshold of 34,664 USD apixaban has a 95 %
probability of being a cost-effective alternative compared
to warfarin.
Because warfarin is not the only AVK available in
Argentina, we perform a separate analysis considering
the cost for acenocoumarol. In this case the cost per life
year gained was 745.20 USD and the cost per QALY




Net Cost USD 135,06
Net Life Years 0,164
Net QALYs 0,172
ICER
Cost per Life Year gained USD 823,29
Cost per QALY gained USD 786,08
Cost per Stroke Avoided (Ischemic and
Hemorrhagic)
USD 5.422,01
Cost per Bleed Avoided (ICH including HS and
Major Bleed)
USD 3.268,66
Fig. 2 Tornado sensitivity analysis of the incremental cost-effectiveness ratio of Apixaban compared with warfarin. The solid vertical line represents the
base-case incremental cost-effectiveness ratio. In the vertical lines are depicted the range obtained for a variable while the others are constant.
MI: myocardial infarction; CV: cardiovascular hospitalization; ICH: intracranial hemorrhage; Monitoring visit: applied only to patients treated with warfarin;
AFtrialRate: treatment´s discontinuation rate; OMB: other major bleed
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would alter our results. Because there is no specific
long-term investment rate in Argentina we run the ana-
lysis raising the discount rate to 10 % and 15 %. For the
10 % cost discount rate the cost per life year gained was
798.26 USD and the cost per QALY gained was 762.18
USD. For the 15 % cost discount rate the cost per life
year gained was 811.28 USD and the cost per QALY
gained was 774.61 USD.
Finally, we assessed different scenarios based on time
horizon. For a 2 year scenario the cost per life year
gained was 17043.00 USD and the cost per QALY gained
was 6153.35 USD. For a 5 year scenario cost per life year
gained was 3624.11 USD and the cost per QALY gained
was 2234.97 USD.
Discussion
Our study estimated that apixaban is a cost-effective op-
tion, compared to warfarin, for the management of
NVAF with an ICER of 786.08 USD/QALY. Local epi-
demiological data regarding AF in Argentina revealed
that subjects suitable for oral anticoagulants are older
and have a higher stroke risk (assessed by the CHADS2
score) than patients included in clinical trials [12]. We
also found that the TTR is less than optimal in more
than two third of the centers in Argentina. These find-
ings are particularly relevant when the clinical effective-
ness of apixaban is assessed versus vitamin K antagonist
warfarin. In fact, considering the results of the model,
apixaban use resulted in fewer thrombotic and bleeding
events than warfarin, leading to less health resource
utilization. Therefore, in spite of the much higher drug
cost for apixaban, the strategy of adopting this novelanticoagulant results in an incremental cost of only
135 USD in a lifetime scenario. Even considering the
cost for acenocoumarol instead of warfarin in a sensitivity
analysis, the ICERs obtained were consistent with the
cost-effectiveness of apixaban over all other options.
The definition of a willingness to pay threshold for in-
cremental effectiveness is a matter of debate in countries
that lack a defined value, as happens in the United King-
dom [38]. The adoption of the WHO Choice rule, using
the GDP per capita as a parameter to set thresholds, is a
valuable strategy in developing countries [35]. In the
case of Argentina, which has three different payers’ sub-
sectors, this method for establishing a threshold provides
a wide reference for decision-makers. Therefore, the use
of sensitivity analysis as a way to manage uncertainty
provides a range of costs-effectiveness ratios that im-
proves availability of data for decision-makers [39].
Our results are concordant with published cost-
effectiveness analysis from other countries reporting that
apixaban is a cost-effectiveness alternative. Canestaro
et al. [16] reported for the United States, that apixaban
is the optimal anticoagulant resulting in a net effective-
ness increment of 0.41 QALY compared with warfarin.
Accordingly, using the same model, Dorian et al. re-
vealed that in the United Kingdom, apixaban improved
both life expectancy and quality adjusted-life years com-
pared to warfarin. Both studies, which used different
cost data, revealed that apixaban is the most cost-
effective therapeutic alternative.
The development of local data is of capital importance
in the process of health technology assessment. More-
over, considering that most physicians in Argentina re-
quire that a medical technology is fully tested before
Fig. 3 a Probabilistic sensitivity analysis of the incremental cost-effectiveness ratio of Apixaban compared with warfarin. b Acceptability curve for
Apixaban compared with warfarin. a Upper threshold per QALY gained: 34664 USD; Lower Threshold per QALY gained: 11558 USD. b Probability
of being accepted as a cost-effectiveness alternative considering the upper and lower thresholds showed in figure 3a
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both clinical and economic aspects will certainly con-
tribute to the decision making process.
Our study has many limitations. Local data are scarce
and it is difficult to obtain needed data in published re-
ports. This reflects problems regarding scientific publica-
tions in Argentina [41]. As a consequence, the relative
weight of local experts’ opinion in validating information ismuch higher than in other countries. This issue has many
potential consequences over results. The introduction of
biases in expert’s responses (such as anchoring effects,
absolute and relative judgements) are one of the most
important factors to be taken into account when results
are considered [42]. Finally, in recent years Argentina
developed economic instability which could represent
an objection with the discount rate adopted in this report
Giorgi et al. Health Economics Review  (2015) 5:17 Page 9 of 10despite that there have not been any discounting modifica-
tions in regional recommendations for conducting health
economic evaluations.
Conclusions
In our study, using local epidemiological estimates and
based on randomised clinical trials data, apixaban resulted
a cost-effectiveness alternative to warfarin according to
local willingness to pay thresholds.
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